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Abbreviations
CDG- Chronic Granulomatous Disease
ICA- Inter-Cellular Adhesion
MRSA- Methicillin Resistant Staphylococcus Aureus
PAS- Phage-Antibiotic Synergy
SA- Staphylococcus Aureus
VRSA- Vancomycin Resistant Staphylococcus Aureus
Introduction
One of the growing challenges in healthcare is the rising occur-
rence of antibiotic resistance. Many pathogens have developed 
resistance to an array of drugs; the discovery of new antibiotics 
has not been keeping up with the rate of the evolving antibiotic 
resistant bacteria. Many are concerned that the medical world 
may return to the times when small infections will be lethal.
For example, Methicillin Resistant Staphylococcus Aureus (MRSA) 
is an example of a bacterial strain that is resistant to every an-
tibiotic except for Vancomycin.  This bug is responsible for most 
hospital acquired infections., and these bacteria can colonize any-
where from surgical sites, lungs, blood, heart, skin and even brains. 
(Jensen et al., 2015). Unfortunately, there has been a recent dis-
covery of Vancomycin Resistant Staphylococcus Aureus (VRSA). 
The emergence of VRSA and its dangers have lead scientists and 
medical doctors to worry about the future of medicine. 
Felix d’Herelle co-discovered bacteriophages in the early 1920s. 
Bacteriophage therapy utilizes the killing powers of nature’s pred-
ators for bacteria; bacteriophages. Interest in phage therapy, and 
its associated research diminished once Flemings discovered the 
curative powers of penicillin. However, Russia and many Eastern 
European countries have continued studying this topic. The grow-
ing need for alternative treatments for bacterial infections gives rise 
to a resurgence of interest in this novel topic (Pincus et al., 2015). 
A bacteriophage is a virus that binds to receptors that are only 
found in bacterial cells.  Bacteriophages infect bacterial cells, 
reproduce and then lyse their host bacteria. Then the origi-
nal phage’s offspring then spreads and infects more bacterial 
cells. Bacteriophages have a specific receptor site and are thus 
antibacterial to a narrow range of bacterial cells. In addition, 
their specificity prevents them from infecting human cells. 
Bacteriophage therapy seeks to harness these powers and use 
them to treat human infections (Jensen et al., 2015).
Scientists are hopeful that bacteriophage therapy will success-
fully treat infections caused by many pathogens, specifically the 
hard to treat MRSA infections. Since research on this topic is 
fairly new, clinical trials need to be run prior to its institution in 
standard medicine. This paper will review some of the different 
experiments and their outcomes. The author wishes to determine 
how these experiments will impact the future of phage therapy.
Phage Infection Mechanism
Bacteriophages are viruses that infect bacterial cells. They are 
found all over the planet. The phages infect bacterial cells by bind-
ing the tips of their tails to receptor molecules on the bacterial 
cell. The viral DNA is then injected into the host cell. The virus 
now directs the creation of more phages, which can be created in 
less than thirty minutes. The phage bursts out of the bacterial cell, 
thereby killing the bacteria. The released phage’s offspring contin-
ue to infect more bacterial cells (Pastagia et al., 2013).
Bacteriophages produce two proteins in order to lyse the cell: Holin, 
creates a pore in the bacterial cytoplasmic membrane, and Lysin in-
teracts with the peptidoglycan in the cell wall. Lysin cleaves to the 
peptidoglycan bonds and ruptures the cell wall. Unable to withstand 
the osmotic pressure, the cell wall bursts (Wang et al., 2000). The re-
leased phages can then continue the cycle of infecting bacterial cells.
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Narrow Host Range
As a bacterial virus, bacteriophages can be extremely host spe-
cific. Consequentially, they exhibit some major advantages in 
comparison to broad spectrum antibiotics. For instance, using 
phages to rid the body of infections does not pose a problem to 
the normal flora, whereas antibiotic treatments impact normal 
flora. The downside to the phage specificity is the rapid ability of 
the bacterial viruses to develop resistance, thus increasing the 
risk that the therapeutic effect is merely transient. 
One way to circumvent this problem is to create a personalized 
phage cocktail specifically for each patient. This would entail 
culturing every infection, and then creating a specific mixture 
of bacteriophage from a phage library. This would ensure that 
the specific viruses could be combined in accordance with the 
different infectious pathogens present in the patient.  In order 
for this to be a viable treatment option, the hospital would need 
to have a broad range of bacteriophage present at all times. One 
group of researchers studied how probable it is to have a wide 
resource of phages to treat infections.
The researchers purchased many strains of antibiotic resistant 
bacteria from both a lab and a hospital. In order to isolate the 
bacteriophages, they filtered sewage waste and then centrifuged 
the supernatant. Finally, the bacterial viruses were purified three 
times by plating and re-plating the plaques.
After multiple attempts, the researchers discovered that only one 
out of 117 strains of bacteriophages were effective against MRSA. 
After obtaining more samples of the bacterial viruses from other 
sources, the researchers still had difficulty isolating effective phage. 
The study resulted in the realization that it is not feasible to treat 
MRSA infections on demand; isolating effective strains presents 
significant challenges. In order to treat these infections, pre-made 
wide range cocktails would have to be available. It is important 
to note that on demand discovery of phages does seem possible 
for other bacterial pathogens such as Pseudomonas aeruginosa, 
Salmonella, and E. coli. Treating these infections with personalized 
cocktails is a viable option (Mattila et al., 2015).
Combination of Phage and Antibiotic Therapy
One way to use bacteriophage to combat infections is to com-
bine phage therapy with antibiotic therapy. The combination of 
phages and antibiotics so far seems to be synergistic; the interac-
tions between the two antibacterial agents provide a combined 
effect that is greater than the sum of the individual effects. One 
phenomenon that has been noted is called phage-antibiotic syn-
ergy (PAS). Research shows that administering sub-lethal doses 
of antibiotics brings about this effect, regardless of whether the 
pathogen is a multi-resistant or naïve bacteria or whether an 
old or new antibiotic is used. 
Evidence suggests that a high dosage of antibiotics leads to a 
tremendous evolutionary advantage for antibiotic resistant 
pathogens. So, combining phage and antibiotics may be the solu-
tion to the medical dilemma. A lower dosage can be used to 
target naïve bacteria, and the bacteriophage can simultaneously 
inhibit the growth of the antibiotic resistant strains (Torres-
Barceló et al., 2016).
Concerns in PAS Treatment
There are some concerns about the negative effects that can 
occur as a result of this two-fold treatment. Although there is 
no research that provides a basis for these fears, in order to 
ensure the complete safety of all patients, it is imperative to 
keep these concerns in mind. One major concern is regarding 
the possibility of breeding double resistant strains of a pathogen. 
This fear is an outgrowth of a similar phenomenon that has 
been noted for some antibiotic combination therapy (Torres-
Barceló et al., 2016). 
Researchers must also be mindful of specific antibiotic-phage 
combinations that inhibit the effectiveness of each individual 
component. For example, phages can block the bacteria’s ability 
to absorb the antibiotic, or the antibiotic may affect the host 
in a way that limits the phage’s ability to infect the bacteria or 
to produce sufficient offspring. Thorough screening of all the 
various combination before treatment can easily eliminate this 
concern (Torres-Barceló et al., 2016). 
Finally, researchers caution that PAS may increase the virulence 
factors of certain infections. This phenomenon can be seen in 
the instance of quorum sensing, the communication between 
different bacteria cells, which can coordinate the production of 
some virulence factors. It has been observed that certain ex-
posure to either phages or antibiotics has produced increased 
virulence. However, the bacterial viruses that target quorum 
sensing receptors can inhibit this response. Although there is 
little or no research indicating that these concerns are obstacles 
to the use of bacteriophage therapy, proper research must be 
done before combining antibiotics and phage therapy in treat-
ment of infections (Torres-Barceló et al., 2016).
Isolation and Host-Range Determination of 
Bacteriophage
n order to harness the therapeutic powers of phages, the ther-
apeutic index must be carefully studied and documented. One 
group of researchers bought bacterial cells from labs and public 
facilities. They isolated the methicillin resistant strains on agar 
plates. The next step required that they isolate the virulent 
phages. Upon obtaining samples from the environment, the re-
searchers purified the samples by filtration and centrifugation 
three times (Jensen et al., 2015).
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In the study they discovered 12 bacteriophages that exhibit lytic 
activity against SA and MRSA. In order to determine the host 
range, they took spectrophotometric assays of the cultures of 
phage-treated bacteria and performed spot testing. After fur-
ther testing the cocktails on fabric and on glass, they found that 
the bacteriophage viruses were able to reduce the colony count 
on cultures of fabric and glass. Interestingly, the phage cocktails 
showed greater lytic activity against human MRSA then against 
non-human Staphylococcus Aureus (SA) and against methicil-
lin-susceptible SA.  In conclusion, they isolated 6 unique lytic 
phages that show strong lysis of MRSA (Jensen et al., 2015). The 
information gathered from this research now opens the door 
to further studying of these specific bacteriophages. In order to 
advance the applications of this study in medicine, the efficiency 
of these phages need to be clinically tested in humans.
Phage Treatment Viability
In order for the bacteriophage to be therapeutically useful, 
there must to be a way to store it in pharmacies. In order to 
examine phage viability, researchers stored phage in the freezer, 
refrigerator, and at room temperature. They concluded that the 
phage was most stable at room temperature, and was almost 
100% viable after 60 days (Pincus et al., 2015). This is a positive 
discovery for the future of phage therapy, as the shelf life seems 
to be suitable for pharmaceutical storage and sale.
Isolation of Phages and Host Range 
Determination
Another area of life in which MRSA affects humans is its ability 
to infect livestock. Generally, animals are not harmed by these 
infections. However, they can be responsible for the transfer of 
infectious bacteria to humans, and this transmission has been 
documented. In particular, farmers and vegetarians who experi-
ence greater exposure to livestock are at a higher risk for this 
kind of infection. One group of researchers isolated three bac-
teriophages that were found in pig farms and tested the effec-
tiveness of their antibacterial qualities (Kraushaar et al., 2013). 
The methods used in the experiment are as follows. Researchers 
purchased bacterial strains, specifically MRSA CC398 strain 10-
1355, from a laboratory. The phages were taken from a variety 
of sources including dust swabs, nasal swabs, and fecal swabs 
from four German pig farms. They then centrifuged, filtered, and 
tested the phages on MRSA lawn. The host range was tested on 
agar plates of 86 different MRSA strains CC398 strains and 34 
other MRSA strains. The researchers also analyzed the DNA of 
the phages. None of the analyzed phages contained known vir-
ulence or resistant genes. Hence, the study could be conducted 
without concern that the phages would eventually cause more 
harm than good to the human host.
The MRSA strains belonging to complex 398 are commonly 
found on pig farms. These researchers aimed to combat live-
stock-associated MRSA infections by discovering the phages 
that naturally inhibit this pathogen. They screened 91 samples. 
Twenty percent of the samples exhibited lytic activity. An inter-
esting phenomenon was noted in the course of this process. 
One of the farms was negative for both MRSA and anti-MRSA 
bacteriophages. This discovery is important, because it con-
notes that phages are found in proximity to the bacteria that 
they infect. Thus, researchers can assume that if they have a 
bacterial pathogen it is likely that phage can be isolated from 
that environment (Kraushaar et al., 2013). This can simplify the 
process for future research as the knowledge of where to find 
the right phages is now known.
Genetics’ Effect on Phage Efficiency
The researchers studied three phages that are genetically related. 
The three PSa phages interestingly infect the same wide range 
of bacteria. Twenty- four MRSA strains were infected by these 
phages. These phages all have a receptor that researchers believe 
may be lipoteichoic acid. Of the three PSa types, type two and 
type three reduced the numbers of a specific MRSA strain more 
efficiently than type one. This aspect was observed with wider 
clearings on agar plates, but the plaques produced by type two 
and type three were ten times more reductive that the plaques 
produced by type one.  The genotyping of the three phage’s genes 
indicates that this property is a result of the differences in the 
lysis genes (Kraushaar et al., 2013). Further examination of the 
genes that favor greater bacterial lysis would be the next step in 
producing antibacterial cocktails for human medicine.
Another interesting result of this experiment was the discovery 
of mutant bacteria that were resistant to the phages used in the 
study. Even when the three different phages were combined in 
one cocktail, they still did not harm the mutant cells. This discov-
ery is important as it highlights the necessity of combining more 
diverse phages in a cocktail to prevent resistance to similar phag-
es (Kraushaar et al., 2013). This is another area of research that 
can be expounded upon based on the findings of this experiment.
Phage Therapy and Host Immuntiy
An important aspect of phage therapy research is the determi-
nation of specific bacteriophage’s therapeutic index. Additionally, 
it is vital to explore if the bacterial virus is equally effective in all 
human hosts or if different factors contribute to the optimal pro-
ductivity of the bacteriophage. One study explored the efficiency 
of phage SATA-8505 and its ability to prevent and treat infections 
caused by the MRSA strain USA300. The therapeutic index was 
examined in vitro with human cells and in vivo in mice. This spe-
cific strain was selected due to earlier research that proved its 
efficiency in combating MRSA USA300 (Pincus et al., 20). 
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All materials for the experiment, MRSA strain USA300, bac-
teriophage SATA-8505, and the phages were obtained from 
laboratories.  Using agar plates, the researchers were able to 
confirm that phage SATA-8505 has the ability to kill MRSA 
USA300. This phenomenon was seen when they observed the 
colony morphology of culture plates two to four hours after 
phage inoculation. 
Once it was clear that the phages were effective killing agents of 
MRSA, the researchers inoculated the mice with MRSA patho-
gens immediately after they injected bacteriophages into the 
skin. They then measured the diameters of the skin lesions for 
six consecutive days. The mice that were treated with an equal 
concentration of phages and bacteria displayed smaller skin le-
sions than the control group. The researchers also used Chronic 
Granulomatous Disease (CDG) immuno-deficient mice. CDG 
patients are more susceptible to MRSA infections due to their 
problematic neutrophil response.  Interestingly, the CDG mice 
developed bigger skin lesions than the healthy mice; usually 
CDG patients develop MRSA infections on deep tissue, such 
as the liver. (Pincus et al, 2015). This could be a positive sign, for 
despite the fact that the skin lesions were big, the infections 
resembled those of healthy patients. One may think that due 
to the large lesion size, the CDG mice did not benefit from 
the phage therapy. Upon further examination, one may conclude 
that these mice improved relative to their own individual states 
of immunity and infection.
Unfortunately, the phage treatment does not seem to be a 
magical injection. Both groups of mice exhibited an increased 
lesional inflammatory cytokines.  The fact that the actual lesion 
size was reduced while the bacterial count and cytokine re-
sponse did not decrease led the researchers to hypothesize that 
although the administered dose of phage reduced the ability of 
the bacteria to inflict toxin-generated damage, it did not affect 
the viability of USA300 (Pincus et al., 2015).  These researchers 
did a complete project. In order to completely understand this 
phenomenon, they repeated the experiment while changing the 
phage dosage and the original bacterial count. They discovered 
that an increase in phage administration brought about an in-
crease in the inflammatory response in the CDG mice. This may 
indicate why bigger lesions that are produced when a higher 
dosage of phage is administered. 
This discovery highlights the importance of phage dosage, espe-
cially in immunocompromised patients. The scientists noted that 
although the phage worked at certain concentrations, when the 
dosage was increased, negative side effects, such as an inflamma-
tion of the infectious site, were observed.  Further research is 
required in order to configure the optimal dosage for treating 
patients while incurring minimal or no harm. The researchers 
make a point in warning clinicians that before phage therapy is 
used on any immuno-deficient individual, the dosage must be 
reconfigured. Extrapolating data from healthy individuals would 
not work for the CDG patients who were more affected by 
increases in dosage.
Once researchers noted that the phages induced an inflam-
matory response in mice, they investigated whether a similar 
response could be noted in human cells. When human blood 
cells were exposed to dosages of phage, the human cells did 
not produce inflammatory responses. The response of human 
keratinocytes was also investigated. When compared to the di-
luent treatment, phage induced a small, yet significant, cytokine 
response (Pincus et al 2015). This is a potential roadblock in the 
implementation of phage therapy. The only way this treatment 
could work is if the scientists find a way to inhibit the human 
body’s negative response to the phage itself.
The next step involved investigation of the impact of phage SATA-
8505 on human blood in both healthy and immuno-deficient indi-
viduals. Unfortunately, the phage did not seem to affect bacterial 
growth or colony morphology. The bacteria cells that were ex-
posed to phage in blood and were then re-cultured grew just as 
well as bacteria that were unexposed to bacteriophage. The re-
searches further investigated the phage and bacterium used and 
found that the bacterial cells were killed by the phage in a culture 
plate. This negates the possibility that a phage-resistant strain of 
MRSA was used to inoculate the blood sample.  In order to elu-
cidate why the bacteria is unaffected by phage in the presence of 
human blood, further research is necessary. 
The last part of this research included the study of the effi-
ciency of SATA 8505 on Vancomycin Resistant Staphhylococcus 
Aruerus (VRSA). The researchers determined that this phage 
is incapable of killing out the VRSA strains (Pincus et al., 2015). 
This observation highlights the strain-specificity aspect of phage 
therapy, since the phage worked fairly well on the MRSA but did 
not affect the VRSA growth.
Strain Specificity
The strain specificity of phage has both positive and negative 
aspects to it. While it is true that phage therapy successfully 
avoids destroying normal flora, one must first determine the 
exact strain of the infection prior to beginning the treatment. 
Unfortunately, this determination often takes time, and while 
treating MRSA infection, time is often of essence. Therefore, 
phage therapy may not yet serve as the first line treatment 
against infections (Pincus et al., 2015).
Thus, possibility of using phage cocktails holds much prom-
ise. Similar to multivalent vaccines, phage cocktails combine 
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a few different strains of bacteriophage. This would increase 
the chances that one of the strains would cover the unknown 
pathogen in the human host. Although this solution seems scien-
tifically sound, there is a financial drawback. Each phage used in 
the cocktail must be separately tested in isolated therapy. Then 
research must be conducted on the combination to ensure that 
the combined effects are positive or synergistic. The added cost 
of all this research may be an issue (Pincus et al., 2015).
Phage Lysins: Pathogen Directed Treatment
One major drawback to phage therapy is the bacteria’s ability to 
develop resistance to phage attachment.  Recently researchers 
have developed ways to purify the lysins from the bacteriophag-
es. The lysins can be used on their own as an antibacterial agent 
by causing bacterial lysis on contact. The use of lysins is gener-
ally limited to bacterial organisms with a cell wall, although re-
searchers are searching for lysins with Gram-negative bacterial 
activity (Pastagia et al., 2013).
Lysin Mechanism
The lysins have two main functions: substrate recognition and 
enzymatic hydrolysis. The N-terminal domain enzymatically 
severs specific peptidoglycan bonds. This can be accomplished 
in multiple ways. They can hydrolyze the glyosidic bonds in the 
glycan strand of the cell wall, or the enzymes can hydrolyze 
the cross-bridge. The enzymes may also cleave the amide bond 
which is located between the glycan moiety and the main pep-
tide. There is a level of specificity of lysin binding which is based 
on binding ligands and the specificity of cell wall binding domains. 
Additionally, the lysins bind to their substrates with an affinity 
constant similar to antibodies (Ka  = 6x108). This suggests that 
lysins do not disengage from the receptors after they bind and 
cleave, just like antibodies. This also explains the speed of lysin 
action. Their high affinity constant accounts for their speedy 
identification of their target bacterial cells (Pastagia et al., 2013).
Lysin Clinical Potential
The primary benefit of phage lysins is that, to date there has 
been no documentation of bacterial resistance to phage lysins. 
Additionally, bacteria with thick capsules and bacteria in biofilms 
do not inhibit lysin activity. These reasons are enough to aim 
research toward harnessing bacteriophage lysin antibacterial 
potential.  
Lysins generally exhibit bactericidal activity against the bacterial 
host of the phages they were harvested from. Like bacteriophag-
es, lysins are strain specific, and therefore do not affect normal 
flora. One specific lysin, chimeric lysin (ClyS) has been proven 
to kill MRSA strains along with other staphylococci. Some ly-
sins have been proven to affect a broader range of bacterium 
(Pastagia et al 2013). These kinds of lysins would be a great first 
defense method against infections in which the exact strain of 
pathogenic bacteria is unknown.
Phage Lysin and MRSA Biofilm Eradication
Phage lysins have potential to fight biofilms, a serious health 
problem. All biofilms are harder to treat than planktonic bac-
teria; specific biofilms of antibiotic resistant pathogens, such 
as MRSA are even more difficult.  Biofilms exhibit antibiotic 
resistance up to 1000 times more than planktonic bacterial 
cells (Chopra et al., 2015). These biofilm infections develop in 
patients that have prosthetic objects implanted in their bod-
ies. Phage lysins seem to be the optimal way to combat MRSA 
infections because of the speed of their bactericidal activity, the 
small chances of bacterial resistance, and the low probability 
of it affecting the normal flora. Additionally, the usage of lysins 
allows for all the positive aspects of phage therapy without the 
negative possibilities such as resistant mutations. 
Lysins generally exhibit bactericidal activity against the bacterial 
host of the phages they were harvested from. Like bacteriophag-
es, lysins are specific to bacterial strains and therefore do not 
affect normal flora. One specific lysin, chimeric lysin (ClyS), has 
been proven to kill MRSA strains along with other staphylococ-
ci. Some lysins have been proven to affect a broader range of 
bacterium (Pastagia et al 2013 and sources within). These kinds 
of lysins would be a great first defense method against bacteri-
al infections when exact strain of the pathogenic bacterium is 
unknown.
Research was conducted on the efficiency of phage lysins in 
eradicating MRSA biofilms. The object of this study was to eval-
uate the success of a phage lysin in eradicating old and new 
biofilms alone and in conjunction with antibiotics. The MRSA 
bacteria strain and the antibiotic, Minocycline, were obtained 
commercially. The phage lysin was extracted from phage MR-10 
that had been previously been characterized by the same re-
search group. In order to isolate and confirm their results, the 
team followed a published method for isolating phage enzymes 
(Chopra et al., 2015). This method of obtaining the phage lysin 
left some room for potential error. The research team may have 
made some errors in isolating the original phage, and the meth-
ods that they used originally are not documented in their paper. 
Thus, the whole project could have operated with impure or 
misnomered materials. Conversely, the method they utilized to 
isolate the enzyme leaves little room for error because they 
followed a proven method of isolating the endolysin. They did 
not rely solely on their observations and research.  Additionally, 
they confirmed their results with SDS-PAGE analysis after every 
purification step (Chopra et al., 2015).
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The biofilms were grown in the lab, and their morphological 
characteristics were identified by scanning with electron mi-
croscopy.  The biofilms were developed on coverslips. Two dif-
ferent types of biofilms were formed; ica-positive and ica-neg-
ative. For the first part of the research, both types of biofilms 
were treated with the endolysin. The ica-negative biofilms were 
initially treated with 9 µg/ml. After three hours no significant 
reduction was observed. Even once they increased the duration 
of the treatment, there was no significant reduction. However, 
when the ica- negative biofilms were treated with 18µg/ml of 
lysin a statistically significant reduction was observed after six 
hours. This seemed to be the highest effective dosage for any 
increase in phage lysin concentration did not create a significant 
decrease in bacterial count. Contrarily, the ica-positive MRSA 
biofilm showed a reduction in bacterial cell count with an appli-
cation of 36µg/mL of phage lysin after six hours. Increasing the 
duration to 24 hours did not make a difference in the bacterial 
reduction (Chopra et al., 2015).   Although the two biofilms 
were very similar, the difference in the intra-cellular adhesion 
clearly affected the optimum concentration of lysin needed to 
eradicate the biofilms.
Phage Lysin and Antibiotics
The next step in this research was to examine the combined 
effects of phage lysin with antibiotics in treatment of biofilms. 
They were subjected to both minocycline (a tetracycline antibi-
otic,) and MR-10 endolysin. A significant decrease was observed 
in the first three days of the treatment. After that there was no 
more significant reduction in both forms of the biofilms The 
researchers also conducted this experiment on old biofilm This 
strong unit did not exhibit significant reduction in the cell count. 
They researchers theorize that this observation is a result of 
the two antibiotic agents acting primarily on the top layer of the 
thick biofilm. Other literature clearly states that antibiotics can-
not penetrate deep into the biofilm because of the complicated 
nature of the biofilm matrix. Since the lysins are one time use 
enzymes, it is possible that they acted on the same cells as the 
antibiotic at different receptor sites. This could be the reason 
for the lack of reduction in the very thick biofilms (Chopin et al., 
2015). Based on this theory, one way to combat thick biofilms 
would be continuous application of lysins.  Once they kill out 
the upper layers, the new lysins can kill the cells in the deeper 
layers of the matrix. 
The next step of this research team was to study how sequen-
tial treatment of phage lysin in conjunction with minocycline 
would affect the biofilms. There were two different sequences 
studied with different results.  The first time the researchers ap-
plied endolysin for six hours and then added minocycline before 
incubating overnight. The next time they applied the minocy-
cline first and then the phage endolysin. In comparison to both 
the controls and each other, the second method of sequential 
treatment delivered the strongest significant decrease in bacte-
rial cell count. Figure 1 below compares the difference in total 
bacterial cell concentration from the control group and the two 
separate sequential treatments.  Using the Live/Dead backlight 
kit, the researcher’s stained the biofilms to see the total live and 
dead cells in the biofilm. After the second sequential treatment 
the staining confirmed that the majority of the live cells were 
killed (Chopin et al., 2015).
The positive results of biofilm treatment with three hours of 
minocycline followed by overnight incubation with endolysin 
MR-10 has a two-fold explanation. First, the antibiotic, mino-
cycline eradicated the metabolically active cells. According to 
literature, the active cells are in the upper layers in the biofilm. 
Since the antibiotics cannot penetrate the layers and it is only 
affective on active cells, using it first ensured that there were 
active cells in the biofilm that the antibiotics could access. Next, 
the endolysins were applied. These lysins are small, low molec-
ular weight proteins. Additionally, they act on both growing and 
stationary cells. Therefore, adding the lysins second enabled the 
smaller molecules to penetrate the biofilm and act on the met-
abolically inactive cells (Chopin et al., 2015). This reasoning also 
explains why the first sequential treatment was not nearly as 
successful. The endolysins probably killed the uppermost cells 
first, so subsequent treatment with antibiotics did not have a 
very strong additive benefit. By the time the antibiotic was ap-
plied there was not much more metabolically active cells pres-
ent in the uppermost layer where the antibiotics were able to 
access. Therefore, they did not do as much as they could when 
they were applied first.
MRSA biofilms are another manifestation of the dangers posed 
by this antibiotic resistant bacterium strain. Instead of using 
the whole bacteriophage, this study provided solid research 
that supports the idea that an isolated enzyme from the phage 
will work in eradicating these biofilms. Since the lysins attack 
the peptidoglycan of the bacterial cell, it is a great solution for 
the hard to treat metabolically inactive cells found in biofilms. 
With the foundation of this research, many more studies can be 
conducted in order to isolate other endolysins for all sorts of 
biofilm infections.
Conclusion
Although many are discouraged by the growth of MRSA in-
fections and the lack of treatment options, research suggests 
that bacteriophages may serve as the solution to this medical 
dilemma. Researchers have explored multiple aspects of bac-
teriophages and they have classified numerous strains of an-
ti-MRSA phages. In order for the medical world to harness the 
natural powers of these viruses, more clinical studies must be 
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performed. Scientists must first continue to experiment on an-
imals, in order to rule out all possibilities of the occurrence of 
negative side effects of phage inoculation. After the preliminary 
experimentation on animals has been completed, human trials 
can establish phages as tried and true medicinal option. If sci-
entists continue to diligently explore this topic, there may be 
reason to believe that the world will be rid of the inherent 
dangers of multi-resistant pathogens.
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